adenosine has been researched along with Atherogenesis in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (22.73) | 29.6817 |
| 2010's | 38 (57.58) | 24.3611 |
| 2020's | 13 (19.70) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LH; Huang, L; Li, YZ; Xu, HQ; Yang, C; Zhang, C; Zhao, YY | 1 |
| Cheng, L; Dai, X; Guo, H; Huang, T; Ling, W; Liu, S; Wang, D; Xia, M; Xiao, Y | 1 |
| Cai, Y; Chen, X; Li, J; Wen, Z; Yi, B | 1 |
| Cao, Z; Dong, X; Fu, J; Tu, Q; Wu, F; Xie, H; Xu, H | 1 |
| Fu, Y; Jia, E; Jiang, R; Jiang, Y; Manafhan, Y; Zhou, Y; Zhu, J | 1 |
| Chen, L; Chen, S; Huang, T; Sun, Y; Wang, X; Wu, J; Wu, X; Yang, Q; Yang, X; Zheng, X; Zheng, Y | 1 |
| Bai, Z; Jia, S; Li, Y; Liu, Y; Ma, H; Wang, H; Wang, J; Wang, T; Yan, R; Yang, L; Zhang, G; Zhang, X; Zhao, Y | 1 |
| Cao, Y; Liu, J; Pan, Y; Song, B; Xu, C; Zeng, Y; Zhang, J; Zhao, X | 1 |
| Bednarski, M; Chłoń-Rzepa, G; Hockemeyer, J; Kieć-Kononowicz, K; Kotańska, M; Kubacka, M; Mogilski, S; Müller, CE; Nicosia, N; Pociecha, K; Schabikowski, J; Świerczek, A; Załuski, M | 1 |
| Chu, M; Li, HY; Ming, H; Yu, B; Yu, J; Zhu, H; Zhu, X | 1 |
| Fan, XL; Han, L; Tang, YF; Xu, ZY; Xue, Q; Zhang, BY; Zhang, GX; Zhang, JJ | 1 |
| Chen, K; Chen, X; Gao, C; Jia, Z; Jian, D; Jian, L; Li, M; Liu, Y; Rao, L; Shen, X; Tang, H; Wang, S; Wang, Y; Zhang, W | 1 |
| Cheng, HM; Chien, CS; Chien, S; Chien, Y; Chiou, SH; Huo, TI; Juan, CC; Li, JY; Nguyen, P; Tsai, PH; Wang, ML; Yarmishyn, AA | 1 |
| Gao, X; Wu, Y; Xu, Y; Zhan, S | 1 |
| Baber, U; Vogel, B | 1 |
| Chlopicki, S; Jablonska, P; Jasztal, A; Kutryb-Zajac, B; Lango, R; Mateuszuk, L; Rogowski, J; Sitek, B; Slominska, EM; Smolenski, RT; Toczek, M; Zabielska, MA; Zakrzewska, A; Zukowska, P | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 2 |
| Dobesh, PP; Patel, M | 1 |
| An, X; Bagi, Z; Boison, D; Dong, Z; Fulton, DJ; Hong, M; Huo, Y; Jiang, X; Li, Q; Liu, Z; Toque, HA; Wang, Y; Weintraub, NL; Wu, C; Xu, Y; Yan, S; Yang, Q; Zeng, X; Zhou, Y | 1 |
| Jones, SP; Uchida, S | 1 |
| Carru, C; Erre, GL; Mangoni, AA; Piga, M; Sotgia, S; Zinellu, A | 1 |
| Jeong, LS; Jeong, SJ; Kim, G; Oh, GT; Park, JG; Yu, J | 1 |
| Bulinska, A; Kutryb-Zajac, B; Mierzejewska, P; Slominska, EM; Smolenski, RT; Zabielska, MA | 1 |
| Bartoszewski, R; Bulinska, A; Chlopicki, S; Jablonska, P; Jasztal, A; Koszalka, P; Kutryb-Zajac, B; Mierzejewska, P; Milczarek, R; Serocki, M; Slominska, EM; Smolenski, RT; Sucajtys-Szulc, E; Zabielska, MA | 1 |
| Cheng, J; Huang, H; Ke, Y; Ling, W; Su, X; Xia, J; Xiao, Y; Yang, X; Zhou, Y | 1 |
| Lian, ZQ; Peng, XY; Wang, MJ; Zhu, HB | 1 |
| Fischer, JW; Grandoch, M; Hoffmann, J; Oberhuber, A; Röck, K; Schelzig, H; Wenzel, F | 1 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Francis, SE; Judge, HM; Steiner, T; Storey, RF; West, LE | 1 |
| Chlopicki, S; Kutryb-Zajac, B; Lipinski, M; Rybakowska, I; Slominska, EM; Smolenski, RT; Toczek, M; Zabielska, M; Zukowska, P | 1 |
| Huang, W; Ling, W; Peng, C; Xia, M; Xiao, Y; Zhang, J | 1 |
| Fan, B; Huang, L; Ma, A; Shaul, PW; Zhu, H | 1 |
| Chen, B; Li, J; Zhu, H | 1 |
| Cheng, L; Li, D; Lian, Y; Liu, Y; Mao, X; Mao, Y; Meng, K; Peng, Y; Wang, B; Zeng, Q | 1 |
| Nylander, S; Schulz, R | 1 |
| Ditmarsch, M; Held, P; Himmelmann, A | 1 |
| Amrhein, C; Bindereif, A; Boeckel, JN; Boon, RA; Chen, W; Dimmeler, S; Eriksson, P; Franco-Cereceda, A; Fürtig, B; Gatsiou, A; Hedin, U; Jaé, N; John, D; Keller, T; Lunella, FF; Maegdefessel, L; Manavski, Y; Perisic Matic, L; Rossbach, O; Schwalbe, H; Sigala, F; Stamatelopoulos, K; Stellos, K; Uchida, S; You, X; Zeiher, AM | 1 |
| Bea, F; Blessing, E; Katus, HA; Mogler, C; Preusch, MR; Rusnak, J; Sievers, P; Staudacher, I; Staudacher, K; Uhlmann, L | 1 |
| Arslan, U; Kocaman, SA; Sahinarslan, A; Timurkaynak, T | 1 |
| Bonan, CD; Morsch, VM; Schetinger, MR; Wyse, AT | 1 |
| Anwar, K; Carsons, SE; Chan, ES; Cronstein, BN; Edelman, SD; Fernandez, P; Rao, S; Reiss, AB; Zhang, H | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Armstrong, M; Cannon, CP; Emanuelsson, H; Heptinstall, S; Husted, S; Lawrance, R; Melissa Thornton, S; Storey, RF; Wickens, M | 1 |
| Bluemke, DA; Fernandes, VR; Helle-Valle, T; Jerosch-Herold, M; Lima, JA; Nasir, K; Rosen, BD | 1 |
| Borea, PA; Fogli, E; Gessi, S; Leung, E; Maclennan, S; Merighi, S; Preti, D; Sacchetto, V; Varani, K | 1 |
| Collet, JP; Montalescot, G | 1 |
| Hamad, B; Huber, K; Kirkpatrick, P | 1 |
| Schrader, J | 1 |
| Eltzschig, HK; Robson, SC | 1 |
| Buchheiser, A; Burghoff, S; Ding, Z; Ebner, A; Fischer, JW; Köhrer, K; Lindecke, A; Romio, M; Schrader, J; Viethen, C | 1 |
| Riksen, NP; Rongen, GA | 1 |
| Cronstein, BN; Reiss, AB | 1 |
| Johnston-Cox, HA; Koupenova, M; Ravid, K | 1 |
| Teng, R | 1 |
| Johnston-Cox, H; Koupenova, M; Ravid, K | 1 |
| Carsons, S; Hai, O; Littlefield, MJ; Reiss, AB; Voloshyna, I | 1 |
| Schaper, W | 1 |
| Folsom, AR; Jacobs, DR; Jerosch-Herold, M; Shahar, E; Wang, L | 1 |
| Bartel, T; Erbel, R; Li, Z; Yang, Y | 1 |
| Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M | 1 |
| Cattaneo, M | 1 |
| Arant, CB; Handberg, EM; Johnson, BD; Kerensky, RA; Mankad, S; McGorray, SP; Merz, CN; Olson, MB; Pauly, DF; Pepine, CJ; Reis, SE; Sharaf, BL; Smith, KM; Sopko, G; von Mering, GO; Wessel, TR | 1 |
| Bea, F; Blessing, E; Isermann, B; Katus, HA; Kreuzer, J; Pedal, I; Preusch, MR; Rosenfeld, ME; Yang, SH | 1 |
| Gan, LM; Grönros, J; Wikström, J | 1 |
19 review(s) available for adenosine and Atherogenesis
| Article | Year |
|---|---|
The potential roles of RNA N6-methyladenosine in atherosclerosis.
Topics: Adenosine; Animals; Atherosclerosis; Inflammation; Mammals; RNA | 2022 |
Pathophysiology roles for adenosine 2A receptor in obesity and related diseases.
Topics: Adenosine; Atherosclerosis; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Osteoarthritis; Receptor, Adenosine A2A | 2022 |
Emerging role of METTL3 in inflammatory diseases: mechanisms and therapeutic applications.
Topics: Adenosine; Atherosclerosis; Autoimmune Diseases; Cardiovascular Diseases; Endothelial Cells; Humans; Methyltransferases | 2023 |
RNA modifications in cardiovascular diseases, the potential therapeutic targets.
Topics: Adenosine; Animals; Atherosclerosis; Cardiovascular Diseases; Coronary Disease; Epigenesis, Genetic; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Heart Failure; Humans; Hypertension, Pulmonary; Hypertrophy; Metabolic Syndrome; Methylation; Mice; Microcirculation; Myocardium; Regeneration; Reperfusion Injury; RNA; RNA Processing, Post-Transcriptional; RNA, Untranslated; Transcriptome | 2021 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2017 |
The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.
Topics: Adenosine; Atherosclerosis; Cardiovascular Diseases; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2017 |
RNA Editing: Unexplored Opportunities in the Cardiovascular System.
Topics: Adenosine; Adenosine Deaminase; Animals; Atherosclerosis; Cardiovascular Diseases; Cathepsins; Cyanosis; Heart; Heart Defects, Congenital; Inosine; Mediator Complex; Regeneration; RNA Editing; Salamandridae; Sequence Analysis, RNA | 2018 |
Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence.
Topics: Adenosine; AMP-Activated Protein Kinases; Atherosclerosis; Cytokines; Endothelium, Vascular; Humans; Interleukin-1; Interleukin-6; Methotrexate; Tumor Necrosis Factor-alpha | 2017 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines.
Topics: Adenosine; Animals; Atherosclerosis; Blood Platelets; Cardiotonic Agents; Cardiovascular Physiological Phenomena; Equilibrative Nucleoside Transporter 1; Humans; Inflammation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor | 2016 |
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
Topics: Acute Coronary Syndrome; Adenosine; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Apyrase; Atherosclerosis; Blood Coagulation; Blood Platelets; Cell Communication; Demyelinating Diseases; Epilepsy; Humans; Metabolism, Inborn Errors; Myocardial Infarction; Neoplasms; Platelet Activation; Platelet Aggregation; Seizures; Signal Transduction; Tamoxifen; Thrombosis | 2007 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
Targeting adenosine receptors in the development of cardiovascular therapeutics.
Topics: Adenosine; Animals; Arrhythmias, Cardiac; Atherosclerosis; Cardiovascular Agents; Cardiovascular Diseases; Humans; Insulin; Kidney; Receptors, Purinergic P1; Reperfusion Injury; Signal Transduction | 2012 |
Regulation of foam cells by adenosine.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Atherosclerosis; Cholesterol; Cyclooxygenase Inhibitors; Foam Cells; Homeostasis; Humans; Hypoxia-Inducible Factor 1; Inflammation; Receptors, Purinergic P1; Scavenger Receptors, Class E; Signal Transduction | 2012 |
A2 adenosine receptors and vascular pathologies.
Topics: Adenosine; Animals; Atherosclerosis; Blood Vessels; Humans; Inflammation; Receptors, Adenosine A2; Signal Transduction; Thrombosis; Vascular Diseases | 2012 |
Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Atherosclerosis; Coronary Artery Disease; Drug Interactions; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2012 |
Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors.
Topics: Adenosine; Animals; Atherosclerosis; Foam Cells; Humans; Myocardial Infarction; Receptors, Purinergic P1; Risk Factors | 2012 |
Dipyridamole, an underestimated vascular protective drug.
Topics: Adenosine; Angina Pectoris; Animals; Atherosclerosis; Coronary Circulation; Coronary Vessels; Dipyridamole; Heart; Humans; Myocardium; Nucleoside Transport Proteins; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Vasodilator Agents | 2005 |
5 trial(s) available for adenosine and Atherogenesis
| Article | Year |
|---|---|
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Relationship, Drug; Humans; Integrin beta3; Pharmacogenetics; Platelet Aggregation; Polymorphism, Single Nucleotide; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding Time; Clopidogrel; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Ticagrelor; Ticlopidine | 2006 |
42 other study(ies) available for adenosine and Atherogenesis
| Article | Year |
|---|---|
Epigenetic Upregulation of H19 and AMPK Inhibition Concurrently Contribute to S-Adenosylhomocysteine Hydrolase Deficiency-Promoted Atherosclerotic Calcification.
Topics: Adenosine; Amino Acid Metabolism, Inborn Errors; AMP-Activated Protein Kinases; Animals; Atherosclerosis; Calcinosis; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Epigenesis, Genetic; Glycine N-Methyltransferase; Humans; Mice; Myocytes, Smooth Muscle; RNA, Long Noncoding; S-Adenosylhomocysteine; Up-Regulation; Vascular Calcification | 2022 |
Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
Topics: Adenosine; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Atherosclerosis; Benzhydryl Compounds; Blood Glucose; Glucosides; Inflammation; Lipoproteins, LDL; Macrophages; Mice; NF-kappa B; Plaque, Atherosclerotic; RNA; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Exploration of N6-Methyladenosine Profiles of mRNAs and the Function of METTL3 in Atherosclerosis.
Topics: Adenosine; Atherosclerosis; Cell Line, Tumor; Humans; Methyltransferases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Small Interfering | 2022 |
Exercise Mitigates Endothelial Pyroptosis and Atherosclerosis by Downregulating NEAT1 Through N6-Methyladenosine Modifications.
Topics: Adenosine; Animals; Atherosclerosis; Mice; Pyroptosis; RNA, Long Noncoding | 2023 |
Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE
Topics: Adenosine; Animals; Apolipoproteins E; Aspirin; Atherosclerosis; Gastrointestinal Microbiome; Inflammation; Mice; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |
Antiplatelet Effects of Selected Xanthine-Based Adenosine A
Topics: Adenosine; Animals; Atherosclerosis; Blood Platelets; Rats; Xanthine | 2023 |
IMM-H007, a novel small molecule inhibitor for atherosclerosis, represses endothelium inflammation by regulating the activity of NF-κB and JNK/AP1 signaling.
Topics: Adenosine; Anti-Inflammatory Agents; Atherosclerosis; Chemokine CCL2; Cyclin D1; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-1beta; Interleukin-6; MAP Kinase Kinase 4; NF-kappa B; Signal Transduction; THP-1 Cells; Transcription Factor AP-1; Vascular Cell Adhesion Molecule-1 | 2019 |
METTL14 regulates M6A methylation-modified primary miR-19a to promote cardiovascular endothelial cell proliferation and invasion.
Topics: Adenosine; Aged; Atherosclerosis; Cell Movement; Cell Proliferation; Endothelial Cells; Female; Humans; Male; Methylation; Methyltransferases; MicroRNAs; Middle Aged | 2020 |
METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications.
Topics: Adenosine; Animals; Atherosclerosis; Cells, Cultured; Endothelial Cells; Forkhead Box Protein O1; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Methyltransferases; Mice; Mice, Inbred C57BL; Mice, Knockout; Promoter Regions, Genetic; RNA, Messenger; THP-1 Cells; Transcription, Genetic | 2020 |
METTL3-dependent N
Topics: Adenosine; Animals; Atherosclerosis; Endothelium, Vascular; Epigenesis, Genetic; Human Umbilical Vein Endothelial Cells; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Methyltransferases; Mice; Mice, Inbred C57BL; NF-kappa B; NLR Proteins; RNA Processing, Post-Transcriptional; RNA-Binding Proteins; RNA, Messenger; THP-1 Cells; Transcriptome | 2021 |
Increased activity of vascular adenosine deaminase in atherosclerosis and therapeutic potential of its inhibition.
Topics: Adenosine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Disease Models, Animal; Fluorescent Antibody Technique; Humans; Male; Mice; Mice, Inbred C57BL; Pentostatin; Receptors, LDL | 2016 |
Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation.
Topics: Adenosine; Adenosine Kinase; Adenosylhomocysteinase; Animals; Atherosclerosis; Blood Vessels; Cerebral Cortex; Endothelial Cells; Epigenesis, Genetic; Gene Expression Regulation; Gene Knockdown Techniques; Inflammation; Mice; Mice, Knockout, ApoE; Reperfusion Injury | 2017 |
LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Apolipoproteins E; Atherosclerosis; Bile Acids and Salts; Biosynthetic Pathways; Diet, Western; Gene Expression Regulation; Hypercholesterolemia; Liver; Mice, Knockout; Plaque, Atherosclerotic; Receptor, Adenosine A3; Transcription Factors | 2018 |
Vascular extracellular adenosine metabolism in mice correlates with susceptibility to atherosclerosis.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Deaminase; Analysis of Variance; Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Blood Vessels; Disease Models, Animal; Hypercholesterolemia; Lipids; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Nucleotides; Receptors, LDL | 2018 |
Inhibition of LPS-stimulated ecto-adenosine deaminase attenuates endothelial cell activation.
Topics: Adenosine; Adenosine Deaminase; Animals; Aorta; Atherosclerosis; Cell Membrane; Cholesterol; Endothelial Cells; Exocytosis; Gene Expression Regulation; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Janus Kinases; Lipopolysaccharides; Metabolism; Mice; Pentostatin; Rats; STAT Transcription Factors; Vascular Cell Adhesion Molecule-1 | 2019 |
Inhibition of S-Adenosylhomocysteine Hydrolase Induces Endothelial Dysfunction via Epigenetic Regulation of p66shc-Mediated Oxidative Stress Pathway.
Topics: Adenosine; Adenosylhomocysteinase; Aged; Animals; Atherosclerosis; Coronary Artery Disease; Disease Models, Animal; DNA Methylation; Endothelium, Vascular; Epigenesis, Genetic; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Middle Aged; Oxidative Stress; RNA, Small Interfering; S-Adenosylhomocysteine; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2019 |
The cordycepin derivative IMM-H007 improves endothelial dysfunction by suppressing vascular inflammation and promoting AMPK-dependent eNOS activation in high-fat diet-fed ApoE knockout mice.
Topics: Adenosine; AMP-Activated Protein Kinases; Animals; Atherosclerosis; Blood Vessels; Diet, High-Fat; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Mice; Mice, Knockout, ApoE; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Tumor Necrosis Factor-alpha | 2019 |
Novel effects of adenosine receptors on pericellular hyaluronan matrix: implications for human smooth muscle cell phenotype and interactions with monocytes during atherosclerosis.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Atherosclerosis; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Vessels; DNA Primers; Gene Expression Regulation; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Monocytes; Muscle, Smooth, Vascular; Real-Time Polymerase Chain Reaction; Receptor, Adenosine A3; Receptors, Adenosine A2; Receptors, Purinergic; RNA, Messenger; Signal Transduction; Vasodilator Agents | 2013 |
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.
Topics: Adenosine; Animals; Apolipoproteins E; Atherosclerosis; Blood Platelets; Blood Vessels; Clopidogrel; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2014 |
Extracellular nucleotide catabolism in aortoiliac bifurcation of atherosclerotic ApoE/LDLr double knock out mice.
Topics: Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Extracellular Space; Iliac Artery; Mice; Mice, Knockout; Nucleotides; Receptors, LDL | 2014 |
Increased plasma S-adenosylhomocysteine-accelerated atherosclerosis is associated with epigenetic regulation of endoplasmic reticulum stress in apoE-/- mice.
Topics: Adenosine; Adenosylhomocysteinase; Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Binding Sites; CCAAT-Enhancer-Binding Proteins; Cell Line; Disease Models, Animal; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Heat-Shock Proteins; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Male; Methylation; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; S-Adenosylhomocysteine; Time Factors; Up-Regulation | 2015 |
Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice.
Topics: Adenosine; Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; Cell Line; Cholesterol, HDL; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Protein Transport; Proteolysis; RNA, Messenger | 2015 |
AMP-activated protein kinase attenuates oxLDL uptake in macrophages through PP2A/NF-κB/LOX-1 pathway.
Topics: Adenosine; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Foam Cells; Lipoproteins, LDL; Macrophages; Mice; Mice, Knockout; NF-kappa B; Okadaic Acid; Protein Phosphatase 2; Ribonucleotides; Scavenger Receptors, Class E | 2016 |
A Potential Mechanism of High-Dose Ticagrelor in Modulating Platelet Activity and Atherosclerosis Mediated by Thymic Stromal Lymphopoietin Receptor.
Topics: Adenosine; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Cholesterol, Dietary; Cytokines; Dose-Response Relationship, Drug; Hyperlipoproteinemia Type II; Immunoglobulins; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Phosphatidylinositol 3-Kinases; Platelet Aggregation; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-akt; Purinergic P2Y Receptor Antagonists; Random Allocation; Receptors, Cytokine; Signal Transduction; Tetraspanin 30; Thymic Stromal Lymphopoietin; Ticagrelor | 2015 |
Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation.
Topics: 3' Untranslated Regions; Adenosine; Adenosine Deaminase; Adult; Aged; Aged, 80 and over; Aortic Aneurysm; Atherosclerosis; Carotid Artery Diseases; Cathepsins; Coronary Artery Disease; ELAV-Like Protein 1; Female; Fluorescent Antibody Technique; Gene Expression Regulation; Gene Knock-In Techniques; Gene Knockdown Techniques; High-Throughput Nucleotide Sequencing; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia; Immunoblotting; Inosine; Interferon-gamma; Male; Middle Aged; Real-Time Polymerase Chain Reaction; RNA Editing; RNA Processing, Post-Transcriptional; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Tumor Necrosis Factor-alpha | 2016 |
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis.
Topics: Adenosine; Administration, Oral; Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Disease Models, Animal; Dose-Response Relationship, Drug; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Structure-Activity Relationship; Ticagrelor | 2016 |
The delta fractional flow reserve can predict lesion severity and long-term prognosis.
Topics: Adenosine; Aged; Atherosclerosis; Coronary Artery Disease; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Ischemia; Male; Middle Aged; Prognosis; Retrospective Studies; ROC Curve; Treatment Outcome | 2009 |
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages.
Topics: Adenosine; Antirheumatic Agents; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cells, Cultured; Cholestanetriol 26-Monooxygenase; Cholesterol; Cyclooxygenase 2 Inhibitors; Down-Regulation; Drug Interactions; Foam Cells; Humans; Interferon-gamma; Macrophages; Methotrexate; Monocytes; Receptor, Adenosine A2A; RNA, Messenger | 2008 |
Age, increased left ventricular mass, and lower regional myocardial perfusion are related to greater extent of myocardial dyssynchrony in asymptomatic individuals: the multi-ethnic study of atherosclerosis.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atherosclerosis; Cohort Studies; Coronary Circulation; Electrocardiography; Female; Heart Diseases; Humans; Hyperemia; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Prospective Studies; Sex Factors; Systole; Time Factors; Ventricular Function, Left | 2009 |
Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells.
Topics: Adenosine; Atherosclerosis; Azo Compounds; Coloring Agents; Foam Cells; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-8; Lipoproteins, LDL; Macrophages; MAP Kinase Signaling System; Proto-Oncogene Proteins c-akt; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; RNA, Messenger; U937 Cells; Vascular Endothelial Growth Factor A | 2010 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Fresh from the pipeline. Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2011 |
NT5E mutations and arterial calcifications.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Atherosclerosis; Calcinosis; Fibroblasts; Gene Deletion; Humans; Hydrolysis; Mice; Mutation; Phenotype | 2011 |
NT5E mutations and arterial calcifications.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Adenosine Triphosphate; Antigens, CD; Apyrase; Atherosclerosis; Calcinosis; Fibroblasts; Gene Deletion; Humans; Hydrolysis; Mutation; Phosphoric Diester Hydrolases; Pyrophosphatases | 2011 |
Inactivation of CD73 promotes atherogenesis in apolipoprotein E-deficient mice.
Topics: 5'-Nucleotidase; Adenosine; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Chemokine CCL2; Cholesterol; Disease Models, Animal; Disease Progression; Fatty Acids, Nonesterified; Gene Expression Profiling; GPI-Linked Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; T-Lymphocytes; Time Factors; Triglycerides | 2011 |
Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine.
Topics: Adenosine; Animals; Apolipoprotein A-I; Atherosclerosis; Biological Transport; CD36 Antigens; Cell Line; Cholesterol; Endothelium; Foam Cells; Gene Expression Regulation; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Macrophages; Monocytes; PPAR gamma; Receptors, Adenosine A2; Resveratrol; Stilbenes | 2013 |
Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA).
Topics: Adenosine; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Body Mass Index; Contrast Media; Coronary Circulation; Coronary Disease; Female; Gadolinium DTPA; Humans; Hyperemia; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Risk Factors; Smoking; Vasodilator Agents | 2006 |
Assessment of coronary flow velocity reserve by noninvasive transthoracic Doppler echocardiography in patients with angiographically normal coronary arteries.
Topics: Adenosine; Adult; Aged; Atherosclerosis; Blood Flow Velocity; Contrast Media; Coronary Circulation; Coronary Vessels; Echocardiography, Doppler, Color; Female; Humans; Male; Middle Aged; Young Adult | 2005 |
P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents.
Topics: Adenosine; Atherosclerosis; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor | 2006 |
Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE).
Topics: Adenosine; Atherosclerosis; Biomarkers; Blood Flow Velocity; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Humans; Inflammation; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Risk Factors; Vasodilator Agents | 2007 |
Long-term administration of 3-deazaadenosine does not alter progression of advanced atherosclerotic lesions in apolipoprotein E-deficient mice.
Topics: Actins; Adenosine; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Female; Homocysteine; Intercellular Adhesion Molecule-1; Interleukin-10; Interleukin-1beta; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; Transcription Factor AP-1; Tubercidin; Vascular Cell Adhesion Molecule-1 | 2007 |
Adenosine induces dilation of epicardial coronary arteries in mice: relationship between coronary flow velocity reserve and coronary flow reserve in vivo using transthoracic echocardiography.
Topics: Adenosine; Animals; Apolipoproteins E; Atherosclerosis; Blood Flow Velocity; Coronary Vessels; Hyperemia; Male; Mice; Mice, Inbred C57BL; Microscopy, Acoustic; Species Specificity; Vasodilation; Vasodilator Agents | 2008 |